MOMary K. Oerline

Mary K. Oerline

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mary K. Oerline has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adherence to Potassium Citrate, Changes in 24-hour Stone Risk Parameters, and Recurrent Kidney Stone Events

    by Joseph J. Crivelli, Mary K. Oerline, Naim M. Maalouf, Ryan S. Hsi, Noah A. Krampe, Kevin B. Smith, Sara L. Best, Brian T. Denton, Vahakn B. Shahinian, John M. Hollingsworth

    Background: Patient adherence limits the effectiveness of preventive pharmacologic therapy (PPT) for urinary stone disease (USD), highlighting the need for accurate adherence monitoring. We assessed associations between potassium citrate adherence measures, changes in 24-hour urine parameters, and the risk of recurrent stone events. Methods: In this retrospective cohort study, we identified adults enrolled in Medicare with USD, a baseline 24-hour urine collection (2010-2019), hypocitraturia or low urine pH, a prescription for potassium citrate monotherapy, and a follow-up urine collection. We defined two adherence measures: (1) percentage of days covered (PDC) using pharmacy claims and (2) change in urinary potassium between baseline and follow-up divided by medication dose (ΔK/dose). We assessed the association of these measures with changes in urinary citrate and pH using analysis of covariance, and the association between adherence and recurrent stone events using Cox models. Results: Among 793 patients meeting study criteria, 504 (63.6%) were adherent based on pharmacy claims (PDC≥80%) and 389 (49.1%) based on ΔK/dose≥0.5. Compared to PDC≥80%, ΔK/dose≥0.5 had a stronger association with change in urinary citrate ( p p <0.001). Compared to PDC≥80%, patients with PDC<80% had a higher risk of recurrent stone events (hazard ratio [HR] 1.431; 95% confidence interval [CI], 1.049-1.952), whereas ΔK/dose was not statistically significantly associated with recurrent stone events (HR 1.032; 95% CI, 0.740-1.439). Conclusions: There are clinically meaningful differences in potassium citrate adherence measures. ΔK/dose was more strongly associated with the change in urinary citrate and pH. However, only PDC was significantly associated with recurrent stone events.


  • Open Access

    Time Trends in Specialty Palliative Care Consultation for Patients with ESKD

    by Kunal Bailoor, Alexandra J. Vita, Richard A. Hirth, Paula Guro, Mary K. Oerline, John M. Hollingsworth, Areeba Jawed, Vahakn B. Shahinian

  • Open Access

    Correction to: The Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists on 24-Hour Urine Parameters: A Retrospective Cohort Study

    by Jennifer A. Schaub, Mary K. Oerline, Joseph J. Crivelli, Naim M. Maalouf, Sara L. Best, John R. Asplin, John M. Hollingsworth, Vahakn Shahinian, Ryan S. Hsi


  • Open Access

    The Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists on 24-Hour Urine Parameters

    by Jennifer A. Schaub, Mary K. Oerline, Joseph J. Crivelli, Naim M. Maalouf, Sara L. Best, John R. Asplin, John M. Hollingsworth, Vahakn Shahinian, Ryan S. Hsi

    Key Points: In a cross-sectional study, sodium-glucose cotransporter 2 inhibitors were associated with a significant increase in urine volume and urine citrate. Glucagon-like peptide-1 receptor agonists were not associated with any significant changes in 24-hour urine parameters that affect stone formation. Background: Emerging data suggest sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) may lower stone risk. Methods: We characterized 24-hour urine parameters among patients with kidney stone disease receiving these agents using Medicare claims from beneficiaries with urine collections processed by a central laboratory between January 2010 and December 2019. We identified a cross-sectional cohort with diabetes and a prescription fill for SGLT2is or GLP-1RAs within the 6 months preceding their urine collection and matched controls. We additionally identified a subset of patients who performed two collections and had a prescription fill for SGLT2is or GLP-1RAs before the second collection, but not the first. We compared across 24-hour urinary parameters in both cohorts and adjusted for multiple comparisons. Results: The cross-sectional cohort included 124 patients with a prescription fill for SGLT2is (and 620 matched controls) and 349 patients with a prescription fill for GLP-1RAs (and 349 matched controls). Compared with controls, patients on SGLT2is had a higher mean urine citrate (838 versus 636 mg; P < 0.01) and volume (2.4 versus 2.0 L; P < 0.01) with improved calcium phosphate supersaturation (P < 0.01). Lower urine pH and higher sulfate and uric acid were observed in the SGLT2i group (P < 0.01 for each). There were no significant differences in urine parameters with GLP-1RA. In the longitudinal analyses of SGLT2is (59 patients) and GLP-1RAs (154 patients), there were no significant differences in urinary parameters. Conclusions: SGLT2is were associated with higher urine volume and citrate in a cross-sectional cohort. GLP-1RAs were not associated with changes that would reduce stone risk.


  • Preventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease

    by Kumaran Arivoli, Autumn N. Valicevic, Mary K. Oerline, Ryan S. Hsi, Sanjeevkumar R. Patel, John M. Hollingsworth, Vahakn B. Shahinian

    Background: Urinary stone disease is a prevalent condition associated with a high recurrence risk. Preventive pharmacological therapy has been proposed to reduce recurrent stone episodes. However, limited evidence exists regarding its effectiveness, contributing to its underutilization by physicians. This study aimed to evaluate the association between preventive pharmacological therapy (thiazide diuretics, alkali therapy, and uric acid–lowering medications) and clinically significant urinary stone disease recurrence. Methods: Using data from the Veterans Health Administration, adults with an index episode of urinary stone disease from 2012 through 2019 and at least one urinary abnormality (hypercalciuria, hypocitraturia, or hyperuricosuria) on 24-hour urine collection were included. The primary outcome was a composite variable representing recurrent stone events that resulted in emergency department visits, hospitalizations, or surgery for urinary stone disease. Cox proportional hazards regression was performed to estimate the association between preventive pharmacological therapy use and recurrent urinary stone disease while adjusting for relevant baseline patient characteristics. Results: Among the cohort of patients with urinary abnormalities ( n =5637), treatment with preventive pharmacological therapy was associated with a significant 19% lower risk of recurrent urinary stone disease during the 12–36-month period after the initial urine collection (hazard ratio, 0.81; 95% confidence interval, 0.65 to 1.00; P = 0.0496). However, the effectiveness of preventive pharmacological therapy diminished over longer follow-up periods (12–48 and 12–60 months after the urine collection) and did not reach statistical significance. When examining specific urinary abnormalities, only alkali therapy for hypocitraturia was associated with a significant 26% lower recurrence risk within the 12–36-month timeframe (hazard ratio, 0.74; 95% confidence interval, 0.56 to 0.97; P = 0.03). Conclusions: When considering all urinary abnormalities together, this study demonstrates that the use of preventive pharmacological therapy is associated with a lower risk of clinically significant recurrent episodes of urinary stone disease in the 12–36 month timeframe after urine collection, although only the association with the use of alkali therapy for hypocitraturia was significant when individual abnormalities were examined.


  • Hospital variation in outcomes following appendectomy in a regional quality improvement program

    by Peter C. Jenkins, Mary K. Oerline, Andrew J. Mullard, Michael J. Englesbe, Darrell A. Campbell, Mark R. Hemmila